Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation

Virax Biolabs (NASDAQ: VRAX) approved a 1-for-25 share consolidation, effective June 26, 2026.

Rhea-AI Summary

Virax Biolabs (NASDAQ: VRAX) approved a 1-for-25 share consolidation, effective June 26, 2026. Shares will trade on a post-consolidation basis under symbol VRAX with new CUSIP G9495L133.

The move aims to regain compliance with Nasdaq Rule 5550(a)(2) on the $1.00 minimum bid price.

Positive

• 1-for-25 share consolidation to help regain compliance with Nasdaq Rule 5550(a)(2)
• Post-consolidation trading on Nasdaq Capital Market continues under symbol VRAX
• No change to each shareholder’s percentage ownership, aside from fractional share rounding
• Fractional shares rounded up to the next whole share, avoiding loss of value

Negative

• None.

Argus Jun 24 session

-14.78% close to close Open Argus

Details

News Market Reaction – VRAX

In the Jun 24 session, VRAX declined 14.78%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -14.8% in the session following this news. A negative reaction despite positive li...

Analysis

The stock dropped -14.8% in the session following this news. A negative reaction despite positive listing-compliance intentions fits VRAX’s history of weakness after corporate updates. Elevated short interest and an overhang from registered resale shares could amplify downside if sentiment remains fragile.

Key Figures

Share consolidation ratio: 1-for-25 Par value change: US$0.001 to US$0.025 per share Nasdaq minimum bid rule: $1.00 per share +5 more

Share consolidation ratio

1-for-25

Reverse split of authorized, issued and outstanding ordinary shares effective June 26, 2026

Par value change

US$0.001 to US$0.025 per share

Par value per ordinary share following 1-for-25 share consolidation

Nasdaq minimum bid rule

$1.00 per share

Nasdaq Marketplace Rule 5550(a)(2) minimum bid price requirement cited as consolidation objective

Registered resale shares

25,875,000 shares

Ordinary shares covered by F-3 resale registration for existing investors

Private placement proceeds

$5,000,000 gross

December 2025 private placement using pre-funded warrants and options

Expected cash balance

$6.4 million

Unaudited cash expected at March 31, 2026 per April 14, 2026 6-K

Armistice ownership

1,000,239 shares (4.99%)

Beneficial ownership in Schedule 13G/A filed May 15, 2026

Shares outstanding

19,923,432 shares

Ordinary shares outstanding as of April 10, 2026 after warrant exercises

Historical Context

3 past events · Latest: May 26

3 events

1. May 26

   Clinical data update

   24h Move

   -18.2%

   Reported positive early pilot data for ViraxImmune in Long COVID and PAIS.

2. Apr 14

   Strategy update

   24h Move

   -11.1%

   CEO letter outlining strategy, milestones and cash position versus market cap.

3. Mar 31

   ISO certifications

   24h Move

   +35.3%

   Announced ISO 13485 and ISO 9001 certifications for quality management system.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

share consolidation, nasdaq marketplace rule 5550(a)(2), cusip, memorandum and articles of association

4 terms

share consolidation financial

"approved a share consolidation of the Company's authorized, issued and outstanding ordinary shares"

Share consolidation is a process where a company reduces the total number of its shares by combining multiple existing shares into a smaller number of higher-value shares. This can make each share more expensive and potentially improve the company’s image. For investors, it often means their ownership remains the same, but the value of each share increases, which can influence how the stock is perceived and traded.

nasdaq marketplace rule 5550(a)(2) regulatory

"to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) (minimum bid price of at least $1 per share)"

Nasdaq Marketplace Rule 5550(a)(2) sets a minimum share price requirement for companies listed on the Nasdaq Capital Market, typically requiring that a company’s common stock maintain a closing bid of at least $1.00 per share. It matters to investors because failure to meet this threshold can trigger a delisting review, which is similar to failing a safety inspection: the stock may be removed from the exchange or force corporate actions (like a reverse split) that change liquidity, visibility, and how easy it is to buy or sell the shares.

cusip financial

"under the same symbol "VRAX", but under a new CUSIP number of G9495L133"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

View in glossary

memorandum and articles of association regulatory

"filed a fourth Amended and Restated Memorandum and Articles of Association reflecting the Share Consolidation"

Memorandum and articles of association are the founding legal documents of a company: the memorandum sets out the company’s basic purpose and scope, while the articles act as its internal rulebook detailing how the company is run, who has what powers, and how decisions are made. For investors these documents matter because they define ownership rights, voting rules, limits on activities, and procedures for major changes—like a contract and rulebook that determine how their investment can be used and protected.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON, June 24, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that the board of directors of the Company approved a share consolidation of the Company's authorized, issued and outstanding ordinary shares of US$0.001 par value each at a ratio of 1-for-25 effective 26 June 2026 (the "Share Consolidation"). The shareholders approved the Share Consolidation at the adjourned extraordinary general meeting of the shareholders held on Friday, June 12, 2026, at 2.00 p.m. local time at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire.

At the opening of trading on June 26, 2026, the Company's ordinary shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capital Market under the same symbol "VRAX", but under a new CUSIP number of G9495L133. The objective of the Share Consolidation is to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) (minimum bid price of at least $1 per share) and maintain its listing on the Nasdaq Capital Market.

Upon the effectiveness of the Share Consolidation, every twenty-five issued and outstanding ordinary shares of a par value of US$0.001 each will automatically be consolidated into one issued and outstanding ordinary share of a par value of US$0.025 each. No fractional shares will be issued as a result of the Share Consolidation. Instead, any fractional shares that would have resulted from the Share Consolidation will be rounded up to the next whole number. The Share Consolidation affects all shareholders uniformly and will not alter any shareholder's percentage interest in the Company's issued and outstanding ordinary shares, except for adjustments that may result from the treatment of fractional shares. The Company has filed a fourth Amended and Restated Memorandum and Articles of Association reflecting the Share Consolidation with the Cayman Islands Registrar of Companies.

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is developing T cell-based test technologies intended to support an immunology profiling platform. T cell testing may have applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.

For more information, please visit www.viraxbiolabs.com

Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms.

In evaluating these forward-looking statements, you should consider various factors, including: our ability to keep pace with new technology and changing market needs; potential for clinical trials to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of preliminary, interim or top-line data to accurately reflect the complete results of a trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to continue to secure FDA and other regulators' agreement on the regulatory path for ViraxImmune™ or other potential products; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us.

These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2025. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions.

View original content:https://www.prnewswire.com/news-releases/virax-biolabs-group-limited-announces-1-for-25-share-consolidation-302808727.html

SOURCE Virax BioLabs Group Limited

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Virax Biolabs (NASDAQ: VRAX) 1-for-25 share consolidation on June 26, 2026?

Virax Biolabs will consolidate every 25 ordinary shares into one share on June 26, 2026. According to the company, the par value per share will change from US$0.001 to US$0.025, with trading on a post-consolidation basis starting that day.

Why is Virax Biolabs (VRAX) implementing a 1-for-25 share consolidation?

Virax Biolabs states the consolidation’s objective is to regain compliance with Nasdaq Marketplace Rule 5550(a)(2). This rule requires a minimum bid price of at least $1 per share, helping the company maintain its listing on the Nasdaq Capital Market.

How will the Virax Biolabs (VRAX) share consolidation affect existing shareholders?

Each shareholder’s ordinary shares will be combined at a 1-for-25 ratio, but percentage ownership should remain unchanged. According to Virax, the consolidation affects all shareholders uniformly, except for minor adjustments related to rounding of fractional shares to whole shares.

What happens to fractional shares in the Virax Biolabs (VRAX) 1-for-25 consolidation?

No fractional shares will be issued after the 1-for-25 consolidation. According to Virax Biolabs, any fractional share that would result will be rounded up to the next whole share, which may slightly adjust individual holdings but not overall ownership percentages.

When will Virax Biolabs (VRAX) start trading on a post-consolidation basis?

Virax Biolabs ordinary shares will begin trading on a post-consolidation basis at the market open on June 26, 2026. The stock will continue on the Nasdaq Capital Market under symbol VRAX, but with a new CUSIP number G9495L133.

Does the Virax Biolabs (VRAX) share consolidation change the company’s total equity value?

The consolidation changes the number of shares and par value, but not stated total ownership percentages. According to Virax, every twenty-five existing shares become one new share, primarily to address Nasdaq minimum bid price compliance rather than alter overall equity value.